1. Protagonist Therapeutics, Inc. (16 from 32 patents)

2. Pharmacia & Upjohn Company (13 from 523 patents)

3. Affymax Technologies, N.v. (6 from 88 patents)

4. Vicuron Pharmaceuticals Inc. (6 from 23 patents)

5. Versicor, Inc. (5 from 8 patents)

6. Miikana Therapeutics, Inc. (4 from 6 patents)

7. Pfizer Corporation (2 from 4,455 patents)

8. Other (1 from 832,680 patents)

9. Novartis Ag (1 from 3,923 patents)

10. Bristol-myers Squibb Compnay (1 from 3,681 patents)

11. Bristol Meyers Squibb Company (1 from 41 patents)

12. Protaganist Therapeutics, Inc. (1 from 1 patent)

1. 11884748 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

2. 11840581 - α4β7 thioether peptide dimer antagonists

3. 11111272 - α4α7 peptide monomer and dimer antagonists

4. 10941183 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

5. 10787490 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

6. 10626146 - α4β7 thioether peptide dimer antagonists

7. 10407468 - Methods for synthesizing α4β7 peptide antagonists

8. 10301371 - Cyclic monomer and dimer peptides having integrin antagonist activity

9. 10196424 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

10. 10059744 - α4β7 thioether peptide dimer antagonists

11. 10035824 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

12. 10023614 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

13. 9809623 - α4β7 peptide monomer and dimer antagonists

14. 9714270 - a4B7 integrin thioether peptide antagonists

15. 9624268 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases